ICIs, specifically pembrolizumab, atezolizumab, and cemiplimab, were proven to be effective first-line agents in Programmed Cell Death Ligand 1 (PD-L1)-positive metastatic NSCLC in phase-3 trials [8,9,10]. Here, CD274 is linked to non-small cell lung carcinoma.